Stay updated with breaking news from Bayer United. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
$250 million (USD) plant will help produce transformational cell and gene therapies on a global scaleCreating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply...
The Pharmaceutical Journal from the Royal Pharmaceutical Society
Bayer’s Xarelto approved in the UK 2nd February 2021 Bayer’s oral factor Xa inhibitor Xarelto (rivaroxaban) has been approved in the UK to treat venous thromboembolism (VTE) and to prevent VTE recurrence in children. Xarelto will become available to treat and prevent VTE recurrence in children from birth to below 18 years old, at least five days after initial parenteral anticoagulation treatment. The approval comes on the heels of a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2020. The CHMP recommendation ...